Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

PURPOSE: CD40 activation is a novel clinical opportunity for cancer immunotherapy. Despite numerous active clinical trials with agonistic CD40 monoclonal antibodies (mAb), biological effects and treatment-related modulation of the tumor microenvironment (TME) remain poorly understood. PATIENTS AND M...

Descripción completa

Detalles Bibliográficos
Autores principales: Byrne, Katelyn T., Betts, Courtney B., Mick, Rosemarie, Sivagnanam, Shamilene, Bajor, David L., Laheru, Daniel A., Chiorean, E. Gabriela, O'Hara, Mark H., Liudahl, Shannon M., Newcomb, Craig, Alanio, Cécile, Ferreira, Ana P., Park, Byung S., Ohtani, Takuya, Huffman, Austin P., Väyrynen, Sara A., Dias Costa, Andressa, Kaiser, Judith C., Lacroix, Andreanne M., Redlinger, Colleen, Stern, Martin, Nowak, Jonathan A., Wherry, E. John, Cheever, Martin A., Wolpin, Brian M., Furth, Emma E., Jaffee, Elizabeth M., Coussens, Lisa M., Vonderheide, Robert H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667686/
https://www.ncbi.nlm.nih.gov/pubmed/34112709
http://dx.doi.org/10.1158/1078-0432.CCR-21-1047

Ejemplares similares

Ejemplares similares